Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 10526 - 10550 of 12327 in total

N-ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine

Experimental

4-[3-(3-NITROPHENYL)-1,2,4-OXADIAZOL-5-YL]BUTANOIC ACID

Experimental

5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide

Experimental

Adenosine-5'-[Beta, Gamma-Methylene]Tetraphosphate

Experimental

5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine

Experimental

METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID

Experimental
Matched Iupac: … (2R)-N'-hydroxy-N-[(1S)-1-(methylcarbamoyl)-2-phenylethyl]-2-(2-methylpropyl)butanediamide …

TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE

Experimental

(E)-(S)-4-[(S)-4-METHYL-2-((S)-3-METHYL-2{(S)-2-[(5-METHYL-ISOXAZOLE-3- CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-PENTANOYLAMINO]-5-((S)-2- OXO-PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID ETHYL ESTER

Experimental

2G7

2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.
Investigational

Arimoclomol

Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Investigational
Matched Iupac: … 3-[chloro({[(2R)-2-hydroxy-3-(piperidin-1-yl)propoxy]imino})methyl]pyridin-1-ium-1-olate …
Matched Salts cas: … 289893-26-1 …

4-hydroxyphenacyl coenzyme A

Experimental

(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-2-O-{2-[(piperidin-3-ylmethyl)amino]ethyl}-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside

Experimental

Cefbuperazone

Experimental
Matched Iupac: … -{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic ... (6R,7S)-7-[(2R,3S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-3-hydroxybutanamido]-7-methoxy-3 …

Dodecyl sulfate

Experimental

Itepekimab

Itepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)).
Investigational

Reloxaliase

Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
Investigational

XEN-D0501

XEN-D0501 is a tetrahydronaphthyl urea-based selective TRPV1 antagonist being investigated for the treatment of erythromelalgia.
Investigational

CN-201

CN-201 is a humanized anti-CD3/CD19 bispecific antibody.
Investigational

Andarine

Andarine is a non-steroidal selective androgen receptor modulator.
Experimental

Sulfur chloride

Experimental

Calcium oxide

Experimental

APL-030

APL-030 is a orally-active small molecule inhibitor of GCN2.
Investigational

Teprasiran

Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).
Investigational

Omapatrilat

Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling. This drug from BMS was not approved by the FDA due...
Investigational
Matched Categories: … Heterocyclic Compounds, 1-Ring …

Lestaurtinib

Investigational
Matched Iupac: … oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1( …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Displaying drugs 10526 - 10550 of 12327 in total